Gene · 5900
RALGDS: ral guanine nucleotide dissociation stimulator
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RALGDS: ral guanine nucleotide dissociation stimulator. Genes, record 5900. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5900
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q12967 | Ral guanine nucleotide dissociation stimulator | 914 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents19
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 60858 | Q12967 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9319 | Q12967 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 5537 | Q12967 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9319 | Q12967 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 5537 | Q12967 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 71315 | Q12967 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 174286 | Q12967 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 241293 | Q12967 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 241293 | Q12967 | Espacenet |
| US 9506039 B2 | 2016-11-29 | 25 | Q12967 | Espacenet |
1 to 10 of 19
See all 19 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,464
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RALGDS papers | Newest fiscal year |
|---|---|---|---|
| ZIABC010440 | Protein Structure, Stability, and Amyloid Formation | 12 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 11 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 11 | 2025 |
| ZIABC010441 | Biomolecular Recognition and Binding Mechanisms | 11 | 2025 |
| P20GM103446 | Delaware INBRE | 7 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| ZIABC010442 | Method Development: Efficient Computer Vision Based Algorithms | 6 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 5 | 2025 |
| P40OD010440 | Caenorhabditis Genetics Center | 5 | 2025 |
1 to 10 of 1,464Source NIH's project files
See all 1,464 nih grantsPapers1,907
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A RALGEF inhibitor suppresses lung cancer stem cell development and tumorigenesis. | J Biol Chem | 2026 | 42749263 | PubTator, text mining | PubMed |
| Tissue-Engineered Brain-Mimetic Niches to Model Braintropic Triple-Negative Breast Cancer Metastasis. | Tissue Eng Part C Methods | 2026 | 42175838 | PubTator, text mining | PubMed |
| High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study. | Protein Expr Purif | 2026 | 42142681 | PubTator, text mining | PubMed |
| Revisiting RAS family GTPase signaling: effector selectivity and oncogenic bypass. | Biochem J | 2026 | 42017331 | PubTator, text mining | PubMed |
| Systematic and precise interventions for KRAS-mutant cancers. | Exp Hematol Oncol | 2026 | 41827015 | PubTator, text mining | PubMed |
| Development and Evaluation of Benzofuran Oxoacetic Acid Compounds as EPAC1 Activators. | J Med Chem | 2026 | 41826280 | PubTator, text mining | PubMed |
| Fibronectin 1 (FN1)-rearranged Mesenchymal Neoplasms: An Updated Review. | Cancer Genomics Proteomics | 2026 | 41771581 | PubTator, text mining | PubMed |
| Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer. | J Immunother Precis Oncol | 2026 | 41766762 | PubTator, text mining | PubMed |
| Matching heterogeneous cohorts by projected principal components reveals two novel Alzheimer's disease-associated genes in the Hispanic population. | Alzheimers Dement | 2026 | 41755704 | PubTator, text mining | PubMed |
| β-Hairpin-Based Peptide Hydrogels: The Case of MAX1. | Gels | 2026 | 41744972 | PubTator, text mining | PubMed |
1 to 10 of 1,907
See all 1,907 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5900
GET https://conductscience.org/api/genes/v1/5900/patents